Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FATE THERAPEUTICS INCFATE · Entity 5968 | See Remarks | August 04, 2026 | August 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FATE THERAPEUTICS INC
Report date August 04, 2026 · Filed August 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 589,355 |
Reported balance
After 2026-08-04 transaction · row 1
1 source rowRow 1 · 2026-08-04 · Sale · Disposed 38,800 · Balance 589,355 F1: Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 75,000 shares of Common Stock underlying RSUs granted to the Reporting Person on July 29, 2024. These sales were automatically executed pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell-to-cover" transactions and were not made at the discretion of the Reporting Person. F2: Represents the weighted average sale price of the shares sold ranging from $2.415 to $2.540 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 75,000 shares of Common Stock underlying RSUs granted to the Reporting Person on July 29, 2024. These sales were automatically executed pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell-to-cover" transactions and were not made at the discretion of the Reporting Person.
F2: Represents the weighted average sale price of the shares sold ranging from $2.415 to $2.540 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 04, 2026 Filed Aug 5, 2026 20:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 38,800 | $2.46 | $95,405.32 |
DisclosureSEC source: 0001193125-26-335019 · ownership.xml · nonDerivative · entry 1 TAHL CINDY · CIK 0001655472 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 589,355 F1 · kind: Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 75,000 shares of Common Stock underlying RSUs granted to the Reporting Person on July 29, 2024. These sales were automatically executed pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell-to-cover" transactions and were not made at the discretion of the Reporting Person. F2 · price: Represents the weighted average sale price of the shares sold ranging from $2.415 to $2.540 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document |
| May 20, 2026 Filed May 21, 2026 20:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 25,590 | $1.88 | $48,083.61 |
DisclosureSEC source: 0001193125-26-234390 · ownership.xml · nonDerivative · entry 1 TAHL CINDY · CIK 0001655472 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 628,155 F1 · kind: Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 50,000 shares of Common Stock underlying performance-based RSUs granted to the Reporting Person on July 29, 2024. These sales were automatically executed pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell-to-cover" transactions and were not made at the discretion of the Reporting Person. F2 · price: Represents the weighted average sale price of the shares sold ranging from $1.835 to $1.935 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document |
| May 06, 2026 Filed May 7, 2026 20:00 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (Right to Buy) · Derivative | 44,444 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001193125-26-211820 · ownership.xml · derivative · entry 4 TAHL CINDY · CIK 0001655472 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 355,556 Underlying: Common Stock · 44,444 shares Expires 2036-01-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2026, such that all of the shares shall be fully vested and exercisable on January 1, 2029, subject to the Reporting Person's continued service with the Issuer as of each such vesting date. Read SEC document |
| May 06, 2026 Filed May 7, 2026 20:00 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (Right to Buy) · Derivative | 122,220 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001193125-26-211820 · ownership.xml · derivative · entry 3 TAHL CINDY · CIK 0001655472 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,780 Underlying: Common Stock · 122,220 shares Expires 2035-01-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2025, such that all of the shares shall be fully vested and exercisable on January 1, 2028, subject to the Reporting Person's continued service with the Issuer as of each such vesting date. Read SEC document |
| May 06, 2026 Filed May 7, 2026 20:00 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 44,444 | $1.05 | $46,666.20 |
DisclosureSEC source: 0001193125-26-211820 · ownership.xml · nonDerivative · entry 2 TAHL CINDY · CIK 0001655472 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 653,745 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2026 Filed May 7, 2026 20:00 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 122,220 | $1.32 | $161,330.40 |
DisclosureSEC source: 0001193125-26-211820 · ownership.xml · nonDerivative · entry 1 TAHL CINDY · CIK 0001655472 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 609,301 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 15, 2026 Filed Jan 16, 2026 21:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001193125-26-015328 · ownership.xml · derivative · entry 2 TAHL CINDY · CIK 0001655472 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2036-01-14 F2 · derivative.exercise_date: The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2026, such that all of the shares shall be fully vested and exercisable on January 1, 2029, subject to the Reporting Person's continued service with the Issuer as of each such vesting date. Read SEC document |
| January 15, 2026 Filed Jan 16, 2026 21:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-015328 · ownership.xml · nonDerivative · entry 1 TAHL CINDY · CIK 0001655472 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 487,081 F1 · kind: Award of restricted stock units ("RSUs") that vest with respect to 1/4th of the RSUs on each of January 8, 2027, January 8, 2028, January 8, 2029 and January 8, 2030, subject to the Reporting Person's continued service with the Issuer as of each such vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. Read SEC document |
| January 09, 2026 Filed Jan 12, 2026 21:04 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 10,589 | $1.06 | $11,275.17 |
DisclosureSEC source: 0001193125-26-010356 · ownership.xml · nonDerivative · entry 1 TAHL CINDY · CIK 0001655472 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 387,081 F1 · kind: Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 17,500 shares of Common Stock underlying RSUs granted to the Reporting Person on January 15, 2025 and 8,326 shares of Common Stock underlying RSUs granted to the Reporting Person on January 25, 2022. These sales were automatically executed pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell-to-cover" transactions and were not made at the discretion of the Reporting Person. F2 · price: Represents the weighted average sale price of the shares sold ranging from $1.05 to $1.09 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document |
| August 04, 2025 Filed Aug 5, 2025 20:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 9,037 | $1.06 | $9,572.89 |
DisclosureSEC source: 0000950170-25-102983 · ownership.xml · nonDerivative · entry 1 TAHL CINDY · CIK 0001655472 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 397,670 F1 · kind: Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 25,000 shares of Common Stock underlying RSUs granted to the Reporting Person on July 29, 2024. These sales were automatically executed pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell-to-cover" transactions and were not made at the discretion of the Reporting Person. F2 · price: Represents the weighted average sale price of the shares sold ranging from $1.045 to $1.075 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document |
| January 15, 2025 Filed Jan 16, 2025 23:32 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (Right to Buy) · Derivative | 275,000 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0000950170-25-006311 · ownership.xml · derivative · entry 2 TAHL CINDY · CIK 0001655472 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2035-01-14 F2 · derivative.exercise_date: The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2025, such that all of the shares shall be fully vested and exercisable on January 1, 2028, subject to the Reporting Person's continued service with the Issuer as of each such vesting date. Read SEC document |
| January 15, 2025 Filed Jan 16, 2025 23:32 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantCommon Stock | 70,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-006311 · ownership.xml · nonDerivative · entry 1 TAHL CINDY · CIK 0001655472 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 406,707 F1 · security: Award of restricted stock units that vest with respect to 1/4th of the underlying shares on each of January 8, 2026, January 8, 2027, January 8, 2028 and January 8, 2029, subject to the Reporting Person's continued service with the Issuer as of each such vesting date. Read SEC document |
| January 10, 2025 Filed Jan 13, 2025 21:05 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 5,654 | $1.55 | $8,763.70 |
DisclosureSEC source: 0000950170-25-004823 · ownership.xml · nonDerivative · entry 1 TAHL CINDY · CIK 0001655472 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 336,707 F1 · kind: Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 4,504 shares of Common Stock underlying RSUs granted to the Reporting Person on January 20, 2021, and 8,325 shares of Common Stock underlying RSUs granted to the Reporting Person on January 25, 2022. These sales were made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell to cover" transactions and do not represent discretionary trades by the Reporting Person. F2 · price: Represents the weighted average sale price of the shares sold ranging from $1.53 to $1.62 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document |
| July 29, 2024 Filed Jul 31, 2024 22:00 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-088769 · ownership.xml · nonDerivative · entry 1 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 342,361 F1 · kind: These shares were granted pursuant to a restricted stock unit award. 100,000 of the units are subject to time-based vesting and 100,000 of the units are subject to performance-based vesting. 25,000 time-based units will vest on August 1, 2025 and 75,000 time-based units will vest on August 1, 2026, so long as the reporting person continues to serve as an employee of the issuer through each vesting date. Subject to the achievement of specified late-stage clinical and regulatory milestones of the issuer on or before July 29, 2028, half of the performance-based units will vest one year after the achievement of two of three of the milestones, and the remaining 50,000 of the performance-based units will vest on the date one year after the achievement of all three of the milestones, in each case subject to the grantee's continued employment with the issuer through each such vesting date. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:10 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (Right to Buy) · Derivative | 425,000 | $0.00 Strike: $6.76 | $0.00 |
DisclosureSEC source: 0000950170-24-010490 · ownership.xml · derivative · entry 1 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 425,000 Underlying: Common Stock · 425,000 shares Expires 2034-01-31 F1 · derivative.exercise_date: The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2024, such that all of the shares shall be fully vested and exercisable on January 1, 2027, subject to the Reporting Person's continued service with the Issuer as of each such vesting date. Read SEC document |
| January 09, 2024 Filed Jan 10, 2024 21:30 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 10,874 | $4.37 | $47,519.38 |
DisclosureSEC source: 0000950170-24-003652 · ownership.xml · nonDerivative · entry 1 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,361 F1 · kind: Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 6,250 shares of Common Stock underlying RSUs granted to the Reporting Person on January 8, 2020, 4,503 shares of Common Stock underlying RSUs granted to the Reporting Person on January 20, 2021, and 8,326 shares of Common Stock underlying RSUs granted to the Reporting Person on January 25, 2022. These sales were made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell to cover" transactions and do not represent discretionary trades by the Reporting Person. F2 · price: Represents the weighted average sale price of the shares sold ranging from $4.02 to $4.50 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document |
| November 09, 2023 Filed Nov 13, 2023 21:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 24,363 | $2.40 | $58,471.20 |
DisclosureSEC source: 0001209191-23-054968 · doc4.xml · nonDerivative · entry 1 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 153,235 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023. Read SEC document |
| February 06, 2023 Filed Feb 7, 2023 21:18 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (Right to Buy) · Derivative | 425,000 | $0.00 Strike: $6.77 | $0.00 |
DisclosureSEC source: 0001209191-23-007509 · doc4.xml · derivative · entry 1 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,000 Underlying: Common Stock · 425,000 shares Expires 2033-02-05 F1 · derivative.exercise_date: The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2023, such that all of the shares shall be fully vested and exercisable on January 1, 2026, subject to the Reporting Person's continued service with the Issuer as of each such vesting date. Read SEC document |
| January 10, 2023 Filed Jan 11, 2023 21:08 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 11,553 | $5.24 | $60,537.72 |
DisclosureSEC source: 0001209191-23-002977 · doc4.xml · nonDerivative · entry 1 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,598 F1 · kind: Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 6,250 shares of Common Stock underlying RSUs granted to the Reporting Person on January 8, 2020, 4,503 shares of Common Stock underlying RSUs granted to the Reporting Person on January 20, 2021, and 8,325 shares of Common Stock underlying RSUs granted to the Reporting Person on January 25, 2022. These sales were made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell to cover" transactions and do not represent discretionary trades by the Reporting Person. F2 · shares: Represents the weighted average sale price of the shares sold ranging from $5.12 to $5.36 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 20:04 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-22-033481 · doc4.xml · derivative · entry 3 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,210 Underlying: Common Stock · 25,000 shares Expires 2028-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 8, 2021. F2 · derivative.exercise_date: This option is fully vested. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 20:04 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 25,000 | $22.96 | $574,000.00 |
DisclosureSEC source: 0001209191-22-033481 · doc4.xml · nonDerivative · entry 2 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,151 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 8, 2021. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 20:04 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 25,000 | $6.55 | $163,750.00 |
DisclosureSEC source: 0001209191-22-033481 · doc4.xml · nonDerivative · entry 1 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,151 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 8, 2021. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 21:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,567 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-22-022495 · doc4.xml · derivative · entry 5 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,210 Underlying: Common Stock · 5,567 shares Expires 2028-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 8, 2021. F2 · derivative.exercise_date: This option is fully vested. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 21:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (Right to Buy) · Derivative | 19,433 | $0.00 Strike: $4.84 | $0.00 |
DisclosureSEC source: 0001209191-22-022495 · doc4.xml · derivative · entry 4 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,195 Underlying: Common Stock · 19,433 shares Expires 2025-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 8, 2021. F2 · derivative.exercise_date: This option is fully vested. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 21:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 25,000 | $38.85 | $971,250.00 |
DisclosureSEC source: 0001209191-22-022495 · doc4.xml · nonDerivative · entry 3 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,151 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 8, 2021. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 21:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 5,567 | $6.55 | $36,463.85 |
DisclosureSEC source: 0001209191-22-022495 · doc4.xml · nonDerivative · entry 2 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,151 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 8, 2021. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 21:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 19,433 | $4.84 | $94,055.72 |
DisclosureSEC source: 0001209191-22-022495 · doc4.xml · nonDerivative · entry 1 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,584 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 8, 2021. Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 21:06 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (Right to Buy) · Derivative | 53,058 | $0.00 Strike: $39.87 | $0.00 |
DisclosureSEC source: 0000899243-22-003424 · doc4.xml · derivative · entry 2 TAHL CINDY · CIK 0001655472 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,058 Underlying: Common Stock · 53,058 shares Expires 2032-01-24 F2 · derivative.exercise_date: The shares subject to this option vest in 48 equal month installments beginning on February 1, 2022 such that this option will be fully exercisable on January 1, 2026, subject to the Reporting Person's continued service with the Issuer as of each such date. Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 21:06 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantCommon Stock | 33,302 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-003424 · doc4.xml · nonDerivative · entry 1 TAHL CINDY · CIK 0001655472 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,151 F1 · security: Award of restricted stock units that vest with respect to 1/4th of the underlying shares on each of January 8, 2023, January 8, 2024, January 8, 2025 and January 8, 2026, subject to the Reporting Person's continued service with the Issuer as of each such date. Read SEC document |
| January 11, 2022 Filed Jan 13, 2022 21:08 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 536 | $49.15 | $26,344.40 |
DisclosureSEC source: 0001209191-22-003172 · doc4.xml · nonDerivative · entry 2 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,849 F1 · kind: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 6,250 shares of Common Stock underlying RSUs granted to the reporting person on January 8, 2020 and 4,503 shares of Common Stock underlying RSUs granted to the reporting person on January 20, 2021. These sales were made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through "sell to cover" transactions and do not represent discretionary trades by the reporting person. F3 · price: Represents the weighted average sale price of the shares sold ranging from $48.74 to $49.40 per share. Read SEC document |
| January 11, 2022 Filed Jan 13, 2022 21:08 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 4,883 | $48.46 | $236,630.18 |
DisclosureSEC source: 0001209191-22-003172 · doc4.xml · nonDerivative · entry 1 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,385 F1 · kind: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 6,250 shares of Common Stock underlying RSUs granted to the reporting person on January 8, 2020 and 4,503 shares of Common Stock underlying RSUs granted to the reporting person on January 20, 2021. These sales were made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through "sell to cover" transactions and do not represent discretionary trades by the reporting person. F2 · price: Represents the weighted average sale price of the shares sold ranging from $47.72 to $48.71 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 2 through 3. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 21:06 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 643 | $47.15 | $30,317.45 |
DisclosureSEC source: 0001209191-22-003051 · doc4.xml · nonDerivative · entry 2 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,268 F1 · kind: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 15,000 shares of Common Stock underlying RSUs granted to the reporting person on January 7, 2019. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: Represents the weighted average sale price of the shares sold ranging from $46.97 to $47.42 per share. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 21:06 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 7,095 | $46.37 | $328,995.15 |
DisclosureSEC source: 0001209191-22-003051 · doc4.xml · nonDerivative · entry 1 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,911 F1 · kind: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 15,000 shares of Common Stock underlying RSUs granted to the reporting person on January 7, 2019. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: Represents the weighted average sale price of the shares sold ranging from $45.71 to $46.65 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 2 through 3. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 21:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-22-000647 · doc4.xml · derivative · entry 6 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,643 Underlying: Common Stock · 50,000 shares Expires 2028-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 8, 2021. F6 · derivative.exercise_date: This option is fully vested. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 21:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 861 | $60.31 | $51,926.91 |
DisclosureSEC source: 0001209191-22-000647 · doc4.xml · nonDerivative · entry 5 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,006 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 8, 2021. F5 · price: Represents the weighted average sale price of the shares sold ranging from $60.30 to $60.33 per share. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 21:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 27,812 | $59.86 | $1,664,826.32 |
DisclosureSEC source: 0001209191-22-000647 · doc4.xml · nonDerivative · entry 4 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,867 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 8, 2021. F4 · price: Represents the weighted average sale price of the shares sold ranging from $59.30 to $60.29 per share. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 21:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 16,900 | $58.84 | $994,396.00 |
DisclosureSEC source: 0001209191-22-000647 · doc4.xml · nonDerivative · entry 3 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,679 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 8, 2021. F3 · price: Represents the weighted average sale price of the shares sold ranging from $58.26 to $59.25 per share. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 21:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 4,427 | $57.76 | $255,703.52 |
DisclosureSEC source: 0001209191-22-000647 · doc4.xml · nonDerivative · entry 2 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,579 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 8, 2021. F2 · price: Represents the weighted average sale price of the shares sold ranging from $57.26 to $58.18 to per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 2 through 5. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 21:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 50,000 | $6.55 | $327,500.00 |
DisclosureSEC source: 0001209191-22-000647 · doc4.xml · nonDerivative · entry 1 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,006 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 8, 2021. Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 22:43 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantCommon Stock | 60,958 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-066163 · doc4.xml · nonDerivative · entry 1 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,006 F1 · kind: These shares were granted pursuant to a performance-based restricted stock unit award. The units will vest in three approximately equal installments conditioned upon the achievement, on or before December 31, 2026, of up to three specified late-stage clinical and regulatory milestones of the issuer, so long as the reporting person continues to serve as an employee of the issuer through each milestone achievement. Read SEC document |
| October 01, 2021 Filed Oct 4, 2021 20:12 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-058930 · doc4.xml · derivative · entry 5 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,643 Underlying: Common Stock · 50,000 shares Expires 2028-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 8, 2021. F5 · derivative.exercise_date: This option is fully vested. Read SEC document |
| October 01, 2021 Filed Oct 4, 2021 20:12 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 11,844 | $59.68 | $706,861.76 |
DisclosureSEC source: 0001209191-21-058930 · doc4.xml · nonDerivative · entry 4 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,048 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 8, 2021. F4 · price: Represents the weighted average sale price of the shares sold ranging from $59.45 to $60.07 per share. Read SEC document |
| October 01, 2021 Filed Oct 4, 2021 20:12 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 21,844 | $58.96 | $1,287,965.93 |
DisclosureSEC source: 0001209191-21-058930 · doc4.xml · nonDerivative · entry 3 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,892 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 8, 2021. F3 · price: Represents the weighted average sale price of the shares sold ranging from $58.45 to $59.44 per share. Read SEC document |
| October 01, 2021 Filed Oct 4, 2021 20:12 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 16,312 | $58.03 | $946,634.30 |
DisclosureSEC source: 0001209191-21-058930 · doc4.xml · nonDerivative · entry 2 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,736 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 8, 2021. F2 · price: Represents the weighted average sale price of the shares sold ranging from $57.41 to $58.36 to per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 2 through 4. Read SEC document |
| October 01, 2021 Filed Oct 4, 2021 20:12 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 50,000 | $6.55 | $327,500.00 |
DisclosureSEC source: 0001209191-21-058930 · doc4.xml · nonDerivative · entry 1 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,048 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 8, 2021. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 23:08 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,383 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-045182 · doc4.xml · derivative · entry 19 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,643 Underlying: Common Stock · 15,383 shares Expires 2028-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 8, 2021. F11 · derivative.exercise_date: This option is fully vested. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 23:08 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (Right to Buy) · Derivative | 27,685 | $0.00 Strike: $4.89 | $0.00 |
DisclosureSEC source: 0001209191-21-045182 · doc4.xml · derivative · entry 18 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,315 Underlying: Common Stock · 27,685 shares Expires 2025-10-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 8, 2021. F11 · derivative.exercise_date: This option is fully vested. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 23:08 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,932 | $0.00 Strike: $4.84 | $0.00 |
DisclosureSEC source: 0001209191-21-045182 · doc4.xml · derivative · entry 17 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,628 Underlying: Common Stock · 6,932 shares Expires 2025-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 8, 2021. F11 · derivative.exercise_date: This option is fully vested. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 23:08 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,534 | $0.00 Strike: $7.87 | $0.00 |
DisclosureSEC source: 0001209191-21-045182 · doc4.xml · derivative · entry 16 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,534 shares Expires 2023-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F11 · derivative.exercise_date: This option is fully vested. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 23:08 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 50,000 | $84.56 | $4,228,000.00 |
DisclosureSEC source: 0001209191-21-045182 · doc4.xml · nonDerivative · entry 15 TAHL CINDY · CIK 0001655472 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,048 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 8, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.